AWARD NUMBER: W81XWH-12-1-0611

TITLE: Metabolic Signature of Antipsychotics Used in the Treatment of Autism

PRINCIPAL INVESTIGATOR: Nira Ben-Jonathan

CONTRACTING ORGANIZATION: University of Cincinnati Cincinnati, OH 45221

REPORT DATE: December 2016

TYPE OF REPORT: Final

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012

# DISTRIBUTION STATEMENT: Approved for Public Release; Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

		Form Approved						
Public reporting burden for thi		iowing instructions of	OMB No. 0704-0188					
data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202- 4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. <b>PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.</b>								
1. REPORT DATE		2. REPORT TYPE		3	3. DATES COVERED			
December 2016		Final			30SEP2012 - 29SEP2016			
Metabolic Signatu	re of Antipsychotic	s used in the Treatn	nent of Autism	5	a. CONTRACT NUMBER			
motabolio Oigilata	no or / anapoyonou			5	b. GRANT NUMBER			
				Ň	V81XWH-12-1-0611			
				5	C. PROGRAM ELEMENT NUMBER			
6. AUTHOR(S)				5	id. PROJECT NUMBER			
Nira Ben-Jonatha	n							
				5	ie. TASK NUMBER			
				5	of. WORK UNIT NUMBER			
E-Mail: Nira.Ben-	Jonathan@uc.edu							
University of Cinc	innati	) AND ADDRESS(ES)		C	NUMBER			
3125 Eden Ave								
Cincinnati, OH 45	267-0521							
9. SPONSORING / MO	ONITORING AGENCY	NAME(S) AND ADDRES	S(ES)	1	0. SPONSOR/MONITOR'S ACRONYM(S)			
LLC Army Madias	Desserational M	atarial Command						
U.S. Army Medica	a Research and M	ateriel Command						
Fort Detrick, Maryland 21702-5012					NUMBER(S)			
12. DISTRIBUTION / AVAILABILITY STATEMENT								
Approved for Public Release; Distribution Unlimited								
13. SUPPLEMENTAR	Y NOTES	a that first true are and	- <b>f</b> the account of the state					
All rat studies were conducted during the first two years of the award under approved the ACURO protocol.								
14. ABSTRACT								
Atypical antipsych	otics $(\Delta \Delta P)$ are pro-	escribed to millions o	f natients with neuro	nsvchiatric d	isorders Although AAP can ameliorate			
mental dysfunction	ns they have serie	ous metabolic side-e	ffects such as weigh	nt gain the m	etabolic syndrome and increased risk			
of diabetes and ca	ardiovascular disea	ase. The current doar	ma is that the metab	olic side effe	cts of AAP are attributed to their action			
on neuronal circu	its the brain. How	ever, we discovered	expression of funct	tional dopam	ine and serotonin receptors in human			
and rodent adipod	cytes and found th	at these receptors a	re targeted by AAP	. In vivo stu	dies with rats and in vitro studies with			
human adipocyte	s revealed multip	le direct effects of	AAP on adipose t	issue. The	se include increased food intake, fat			
accumulation, enla	argement of adipo	cytes, alterations in k	ey metabolic genes	, changes in	the secretion of leptin and adiponectin,			
suppression of ba	sal and isoprotere	enol-stimulated lipoly	sis, and increased	preadipocyte	e proliferation. We conclude that AAP-			
induced metabolic	induced metabolic dysregulation is caused, in part, by their direct action on adipose tissue, presumably via local dopamine and							
serotonin receptor	r subtypes.							
15. SUBJECT TERMS	5							
Antipsychotics, ac	lipocytes, metabol	ic syndrome, in vivo,	in vitro, dopamine,	serotonin, re	ceptors			
16. SECURITY CLAS	SIFICATION OF:		17. LIMITATION	18. NUMBER	R 19a, NAME OF RESPONSIBLE PERSON			
			OF ABSTRACT	OF PAGES	USAMRMC			
a. REPORT	b. ABSTRACT	c. THIS PAGE	1		19b. TELEPHONE NUMBER (include area			
			Unclassified		code)			
Unclassified	Unclassified	Unclassified		34				
					Standard Form 298 (Rev. 8-98) Prescribed by ANSI Std. Z39.18			

Standard	Form	298 (	(Rev.	8-98
rescribed b	y ANSI	Std. Z3	9.18	

# **Table of Contents**

# <u>Page</u>

Introduction	3
Body	4
Key Research Accomplishments	8
Reportable Outcomes	8
Conclusion	9
References	9
Appendices	10

# Introduction

Atypical antipsychotics (AAP) are used chronically to treat millions of pediatric, adult, and geriatric patients with schizophrenia, bipolar disorder, major depression, post-traumatic stress disorder and autism [1, 2]. While most drugs alleviate neurobehavioral symptoms, many cause serious metabolic side-effects such as weight gain, and the metabolic syndrome [3]. The metabolic syndrome is defined as a cluster of disorders that include obesity, insulin resistance, glucose intolerance, hypertension and dyslipidemia, and is associated with increased morbidity, and high risk of mortality due to cardiovascular disease.

The precise targets of AAPs are unclear, but they bind primarily to dopamine and serotonin receptors [4, 5]. The current dogma is that AAPs bind to these receptors within the brain. Yet, our laboratory discovered that the same receptors are also expressed in adipose tissue [6], where they can be directly activated by the AAP.

Among the most widely prescribed AAP, olanzapine (Zyprexia) and clozapine (Clozaril) carry the greatest risk of the metabolic disturbances, quetiapine (Seroquel) and risperidone (Risperdal) have an intermediate risk, while ziprasidone (Geodon) and

Table 1: Metabolic disturbances associated with selected AAP	

	Weight Gain	Glucose Abnormalities	Dyslipidemia	Metabolic Syndrome	
Olanzapine	High	High	High	High	
Risperidone	Medium	Medium-Low	Low	Medium	
Ziprasidone	Low	Low	Low	Low	

aripiprazole (Abilify) confer lower risks [7]. **Table 1** shows an example of three AAP and their relative effects on weight gain, glucose homeostasis and dyslipidemia. For our studies, we selected Olanzapine and Zipresidone which represent high and low risk of the metabolic syndrome. We also compiled data from various publications

 Table 2: Binding affinities (Ki=nM) of AAP to DAR and 5HTR subtypes

	D1R	D2R	5HT1a	5HT2a	5HT2c	5HT6	5HT7
Olanzapine	31-58	5-20	600-2000	1.5-8	11-14	6	105
Risperidone	61-75	1-8	190-490	0.2-0.6	26-33	2240	6.6
Ziprasidone	30	3-8	1.9-3.4	0.1-3	1.3-13	61	6

on the binding affinities of these AAP to dopaminergic (DAR) and serotonergic (5HTR) receptor subtypes. **Table 2** shows relatively high binding affinities of most drugs to D1R and D2R,

and variable binding affinities to some serotonergic receptors, indicating that they act via multiple mechanisms of action that cannot be ascribed to a single receptor subtype.

# Hypothesis/Objectives

Hypothesis: Adipose tissue, via its endogenous DAR and/or 5-HTR, is a major target of AAP. We proposed that AAP-induced suppression of leptin release from adipocytes leads to increased food intake and weight gain, while the suppression of adiponectin exacerbates the metabolic syndrome. The objectives were to establish adipose tissue as a critical target of AAP and elucidate the mechanisms by which they alter adipose tissue functions. A rat model was used to determine the *in vivo* effects of the drugs and examine the putative role of leptin as the mediator of drug-induced increased appetite and weight gain. Human adipocytes were used to document the *in vitro* effects of AAP on preadipocyte proliferation, gene expression, and lipid accumulation.

# Specific Aims:

- Aim 1: To document the effects of the drugs in a rat model and examine whether drug-induced leptin suppression is a major drive for increased appetite and weight gain.
- **Aim 2:** To determine if weight-inducing AAP increase cell proliferation, stimulate adipogenesis, enhance lipid accumulation and/or alter expression and release of selected adipokines in human adipocytes.

# **Methods**

<u>Rat Model</u>: Adult female Sprague-Dawley rats under normal diet were given cookie dough mixed with Olanzapine or Ziprasidone (4 mg/kg), or vehicle, twice a day for 7 days. Body weight and food intake were measured each day. Body composition by non-invasive NMR was analyzed on days 1,3, and 7. On days 3 and 7, rats were euthanized and subcutaneous (sc) and periovarian (vis) fat was harvested and analyzed by custom-designed PCR arrays for selected adipose-related genes. Incubated rat sc explants or adipocytes were used for analyzing the effects of AAP on multiple parameters.

<u>Human adipocytes:</u> Human subcutaneous adipose tissue was obtained with informed consent from patients undergoing elective abdominoplasty procedures. Preadipocytes and mature adipocytes were isolated by

collagenase digestion followed by differential centrifugation, induced differentiation, and treatment as indicated.

<u>RNA extraction and purification</u>: RNA was isolated using a trizol protocol to remove excess triglycerides and produce crude RNA. Purified DNA-free RNA was isolated from crude RNA using a RNAspin mini kit.

<u>*RT-qPCR:*</u> After reverse transcription, cDNA was analyzed by two methods: 1) custom-designed RNA arrays with 21 metabolic-related genes.  $\beta$ -2 microglobulin (B2M) and hypoxanthine phosphoribosyl transferase (HPRT) were used as reference genes.

<u>Lipolysis:</u> Adipocytes were incubated with various treatments for 72h and then were incubated with (2h) and without (4h) the  $\beta$ -adrenergic agonist isoproterenol in Krebs-Ringers buffer containing 2% BSA. Glycerol release was measured by colorimetry.

<u>ELISA</u>: Paired commercial capture and detection antibodies were used to analyze leptin or adiponectin by respective sandwich ELISAs using fluorometric detection.

# <u>Body</u>

# A. Studies with rats



A1: Effects of AAP on body weight, food intake and body fat in rats

The goal was to compare the effects of treating rats with Olanzapine (Olan) and Ziprasidone (Zip), which

**Fig 1:** Differential increases in body weight, food intake and body fat induced by olanzapine and ziprasidone. Female rats were given 4 mg/kg of drug or vehicle orally twice/day for 7 days. Each value is a mean±SEM of 8 rats.

#### A2: AAP directly Increase the size of rat adipocytes

Sc adipose explants from rats (N=8) were incubated in DMEM/F12 and 5% FBS with vehicle control, Olan (10 and 100 nM) or Zip (10 and 100 nM) for 7 days. Explants were fixed in paraformaldehyde, paraffin-embedded and 8µm sections mounted on slides were stained with H&E and photographed. Using the Adiposoft software, the surface area of adipocytes was measured in six fields in each section in a blinded manner. As shown in **Fig 2**, Olan and Zip at 100 nM increased adipocyte size by 50% and 20%, respectively. The low dose of Olan was ineffective while Zip at a low dose caused a small, but significant, reduction in adipocyte size. These data indicate that the observed *in vivo* effect of the drugs on body weight and body fat in rats were due, in part, to their direct ability to cause enlargement of the adipocytes.



represent high and low risk of

metabolic disturbances, on food

intake, body weight and body

cookie dough mixed with vehicle,

Olan or Zip at 4 mg/kg twice/day for

7 days. Fig 1 shows rapid increases

in food intake and body weight, with Olan exhibiting stronger effects than

Zip. The weight gain was attributed

to fat mass expansion, as confirm

by in vivo NMR. Although the Olan-

induced food intake leveled off after

2-3 days, fat mass continued to rise,

suggesting direct drug effects on fat

Rats were

given

composition.

accumulation.



# A3: Changes in gene expression in sc and vis fat following in vivo treatment of rats with AAP

Our next objective was to determine whether *in vivo* treatment with Olan and Zip alter selected metabolic-related genes. To this end, we used custom-designed PCR array with a carefully selected set of genes, grouped by function into: 1) metabolic components, 2) adipokines/cytokines, 3) transcription factors, and 4) various

receptors. We examined changes in these genes in both sc and vis fat in response to treatment with the two AAP for 3 and 7 days. **Fig 3** shows a complex outcome, with many of the genes suppressed in sc, but not in vis, fat after 3 days. Without exception, olanzapine showed stronger effects than ziprasidone. Several key lipolytic



AAP-induced Fig 3: changes in expression of metabolic-related 17 in sc and genes periovarian (vis) adipose tissue. Female rats were orally-treated for 3 days with olanzapine (Olan), ziprasidone (Zipr) or vehicle. Data are expressed fold as positive negative or changes over controls, after correction for 2 house-keeping genes. Blue dotted line = no change.

enzymes (LPL, ATGL and HSL) as well as transcription factors (PPARγ and c/EBPα) that regulate adipogenesis, were suppressed in sc fat, while FAS, a major enzyme that regulates lipogenesis, as well as Glut4, an insulinregulated glucose transporter, were increased in periovarian fat. Adiponectin and leptin were suppressed in sc fat after 3 days of treatment, while IL-6 and MCP-1 increased after 7 days (data not shown). Insulin receptor expression was moderately suppressed in both fat depots, suggesting induction of insulin resistance. Expression of Srebf1, which regulates lipid homeostasis, significantly increased after 7 days by both drugs (not shown), suggesting a delayed fat accumulation and a potential induction of liver steatosis [8].

Adiponectin, an insulin-sensitizing adipokine [9], was markedly suppressed in sc fat but did not change in vis fat. Unexpectedly, leptin was markedly suppressed by both drugs in sc fat, but increased in response to Olan in vis fat. Since the relative contributions of sc and vis adipose depots to the circulating levels of adipokines is unknown, their direct analysis in serum following drug treatment should provide a true assessment of their impact on targets such as brain, liver or cardiovascular system. Notably, estrogen receptor alpha (ER $\alpha$ ) was reduced, but ER $\beta$ 

was moderately increased in sc fat, while aromatase, which converts androgen precursors to estrogens was suppressed. Future studies should examine the role of gonadal steroids and their receptors in metabolic homeostasis in response to AAP treatment.

# A4: Effects of AAP on prolactin release in rats

To examine for the dopaminergic component of each drug, blood collected on days 3 and 7 of treatment was analyzed for prolactin, a pituitary hormone which is under tonic inhibition by dopamine [10]. **Fig 4** shows 80-100 fold increases in serum prolactin levels in response to Olan, with lesser, but significant, increases in response to Zip, confirming the critical role of D2R in mediating some actions of the AAP on the brain.

# A5: Lack of effects of either leptin or leptin receptor super-antagonist

Leptin, whose release is proportional to fat mass, regulates food intake and energy expenditure [11]. Leptin administration reduces appetite







while its chronic deficiency results in extreme obesity. Being the major satiety hormone, we assumed that drugs that increase appetite do so by suppressing leptin release. The availability of pegylated leptin and leptin receptor super-antagonists from our collaborator, Dr. Gertler [12], provided a unique opportunity for examining the effects of acute hypoleptinemia on food intake and weight gain in rats. Pegylation increases the serum half-life of both compounds from 1 hr to 14 hrs. Our main objective was to use the leptin antagonist to induce severe central leptin deficiency, enabling us to examine the role of leptin as a possible mediator of olanzapine-induced increased appetite and weight gain, presumably by blocking the transport of endogenous leptin into the brain.

Two approaches were initially used to examine the putative role of leptin in mediating AAP actions. We first examined if the leptin receptor antagonist mimics the olanzapine-induced rise in food intake and body weight



**Fig 5:** Suppression of leptin release from mature adipocytes. Cells were incubated with Olanzapine or Ziprasidone for 72 hrs. Conditioned media were analyzed for leptin by ELISA. Each value is a mean±SEM; N=6.

#### B. Studies with primary human adipocytes

gain. Rats were injected ip once a day with 2.5 mg/kg of the pegylated antagonist or vehicle control, followed by analysis of food intake and body weight for 7 days. Disappointedly, there were no differences in food intake or body weight in the antagonist-treated rats (data not shown). We then examined if peguylated leptin abrogates the effects of Olan. Rats were treated with both, daily ip injection of pegylated leptin at 0.5 mg/kg, and twice a day with Olan at 4 mg/kg, followed by the same analyses as above. Whereas Olan caused increases in all parameters, as was shown in **Fig 1**, pre-treatment with leptin did not alter the effects of Olan (data not shown).

Indeed, little or no effect of the AAP on leptin release was also observed using isolated vis mature rat adipocytes. As evident in **Fig 5**, Olan at a high dose of 100 nM caused a small, 15% suppression of leptin release from mature adipocytes, while Zip 100 nM caused 40% inhibition. Given the disappointing *in vivo* and *in vitro* results, we decided to discount our original hypothesis that leptin is a major mediator of AAP actions.

#### <u>B1: Effects of AAP and dopamine on adiponectin and leptin release from mature human adipocytes</u> Using isolated mature human adipocytes, we examined the effects of dopamine sulfate (DAS), Olan and Zip on leptin and adiponectin release.

As shown in Fig 6, a 3 day incubation with 1 nM olan caused >65% inhibition of adiponectin release, while 1 nM Zip had no effects. Notably, 10 nM Olan was less effective than the 1 nM dose, suggesting activation of opposing receptors at higher doses; 10 nM Zip cause 50% inhibition of adiponectin, while DAS was without effects. As was seen using rat adipocytes (Fig 5), Zip was more effective than Olan in suppressing leptin release, but





without an obvious dose-dependent actions. This experiment suggests that future studies should identify which receptors mediate the actions of Olanzapine vs ziprasidone.

#### B2: Suppression of basal lipolysis by the AAP

We next examined the direct effects of AAP on lipolysis, using either isolated mature adipocytes or primary preadipocytes which were induced to differentiate in culture over a 10 day period by incubation with a differentiation cocktail [13]. Cells were incubated with the drugs for 72 hrs, and after media replacement, conditioned media were collected for 4 hrs and analyzed for glycerol by a colorimetric assay. As evident in **Fig 7**, Olanzapine caused dose-dependent inhibition of lipolysis in differentiated preadipocytes, having a similar effect in mature adipocytes except at the higher dose. Ziprasidone was less effective than Olanzapine. These data indicate that the suppression of basal lipolysis by AAP likely contributes to fat accumulation and enlargement of the adipocytes. The non-linear dose-dependence effect suggests activation of various receptors at different doses, an issue that should be examined in future studies by knocking out selected dopaminergic and serotonergic receptors.



# B3: Expression of serotonergic receptors in human adipocytes

Given the increasing evidence for a critical role played by serotonergic receptors as mediators of AAP actions [4], we next examined expression of selected 5HTR in both primary human adipocytes and our LS15 human adipocyte cell line (see below) before and after differentiation (**Fig 8**). As determined by RT-PCR, 5HTR1a was expressed at variable levels by all cells examined, 5HTR7 was expressed in primary preadipocytes and differentiated LS14 adipocytes, while mature adipocytes express only 5HTR2c. Primary preadipocytes also express 5HTR2a and 5HTR6. Since classical RT-PCR is only semi-quantitative, more detailed analysis should be done in the future using quantitative real-time PCR.

### B4: Suppression of lipolysis by DAR and 5HTR agonists

Pooled preadipocytes from several patients were induced to differentiate for





tested 5HTR agonists affected basal lipolysis, while Tan, a HT1A agonist, caused a significant suppression of iso-stimulated lipolysis. These data indicate that the suppression of lipolysis by AAP likely contribute to fat accumulation and enlargement of the adipocytes. This involves activation of various receptors at different doses, an issue that should be examined in future studies by conducting knockout studies of selected dopaminergic and serotonergic receptors.

# C. Studies with LS14 human adipocytes

# C1: Characteristics of LS14 cells

We previously cloned a unique human adipocyte cell line, named LS14, from a patient with a freshly removed liposarcoma [14]. These spontaneously immortalized cells have been maintained in culture for many generations, and were provided to many investigators in the USA and abroad. Extensive characterization

Fig 7: Suppression of basal lipolysis in differentiated human preadipocytes (left panel) isolated or mature adipocytes (right panel). Cells were incubated with Olan or Zip for 72 hrs. Conditioned media collected after 4 hr were analyzed for glycerol release by colorimetry.



**Fig 8:** Expression of serotonergic receptors in human adipocytes, analyzed by RT-PCR. Br: brain, Pr: primary preadipocytes, Ma: mature adipocytes, LS: proliferating LS14, dLS: differentiated LS14, W: no template.

days. The cells were then 10 incubated for 72 hrs with DAR and 5HTR agonists (all at 10 nM doses), washed, and conditioned media were collected for 5 hrs for basal lipolysis. This was followed by cell incubation with 1µM isoproterenol β-adrenergic (Iso), а receptor agonist, and media collection after 2 hrs. Glycerol release was analyzed by a colorimetric assay. As shown in Fig 9. both Fenoldopam, а D1R peripheral agonist, and Cabergoline, а D2R agonist, significantly suppressed basal lipolysis but had no. or little, effect on iso-stimulated lipolysis. None of the revealed that they resemble vis adipocytes and express all the receptors, i.e., DAR and several 5-HTR, as well as adipose-specific markers, as do primary vis adipocytes (**Fig 10**).

# C3: AAP increased the proliferation of LS14 cells

Given their immortality, LS14 cells can be used as a cellular model for studying both: proliferating preadipocytes and fully differentiated mature adipocytes (**Fig 11**).

Using LS14 cells as preadipocytes, we examined the effects of AAP on cell proliferation. Cells were incubated with the drugs for 72 hrs, and cell proliferation was then determined by the Resazurin assay. **Fig 12** shows that Zip increased cell







**Fig 11:** *Left panel:* photographs of proliferating LS14 preadipocytes. *Right panel:* 10 days after induction of differentiation, showing marked changes in cell shape and lipid accumulation, determined by staining with Oil-Red-O.

# Key Research Accomplishments

- AAP administration in rats results in rapid increases in body weight, food intake and adiposity, as reflected by increased adipose tissue mass.
- Multiple metabolic-related genes are altered in both sc and vis fat in response to *in vivo* administration of AAP.
- Olanzapine, known to cause more severe metabolic disturbances in humans, was also potent in causing metabolic alterations in rats.
- Studies with isolated human adipocytes demonstrate direct effects of the AAP on both adipokine release and lipolysis.
- AAP exert direct actions on fat accretion by increasing preadipocyte proliferation as well as by augmenting the size of mature adipocyte.
- Enhanced fat accumulation caused by AAP is also due to the suppression of basal lipolysis.

# **Reportable Outcome**

# Presentations in Scientific Meetings:

- Ben-Jonathan: Antipsychotics induced obesity: Direct actions on the Adipocytes, Invited Speaker, the 2014 Obesity Summit, London, UK, April 2014.
- Eric R Hugo, Randall R Sakai, Eric J Phillips, Sejal R Fox, Vidjaya LV Premkumar, Nira Ben-Jonathan: Direct Effects of Weight-Inducing Antipsychotics on Adipose Tissue from Humans and Rats, Annual Meeting of the Endocrine Society, Chicago, Illinois, June 2014.
- Ben-Jonathan and Hugo: Direct actions of antipsychotics: A cause for metabolic dysregulation. The 7<sup>th</sup> International Congress of psychopharmacology, Antalya, Turkey, August, 2014.

# Manuscripts:

\* Eric R. Hugo, Dana C. Borcherding, Neil M. Richtand, and Nira Ben-Jonathan. Dopamine and Serotonin



Fig 10. Characterization of LS14 adipocytes.

proliferation at all doses tested while Olan was effective as 10 and 100 nM but not at 1 nM. These data indicate that in addition to expanding fat mass by cell enlargement, AAP can increase the pool of preadipocytes that eventually differentiate into lipid filled mature adipocytes.



**Fig 12:** AAP increase the proliferation of human preadipocytes. LS14 cells were incubated with Olan or Zipr for 72 hrs. Cell viability was determined by the Resazurin assay. RFU: relative fluorescence units.

Receptors in Human Adipocytes: Do they Mediate Adverse Metabolic Effects of Antipsychotics? Molecular Medicine (submitted; Appendix 1)

Hugo, Sakai, Phillips, Fox, Premkumar, and Ben-Jonathan: Direct effects of weight-inducing antipsychotics on adipose tissue from humans and rats (Manuscript in preparation).

# **Overall Conclusions**

Collectively, these studies support our major hypothesis that AAP-induced metabolic dysfunctions in patients that are treated with AAP are due, in part, to their direct action on the adipocytes. As predicted by its actions in patients, Olanzapine is more potent than Ziprasidone in affecting lipolysis and adipokine release from human adipocytes. The mechanism of action of AAP is highly complex as it is involved activation of a variety of dopaminergic and serotonergic receptors, release of several adipokines, and reciprocal interactions with many factors that are produced by other target organs, including the brain, liver and the GI tract. Deciphering which of these receptors in adipose tissue is particularly critical would be extremely difficult, necessitating the application of gene silencing of each receptor alone as well as in combination.

# **References**

- C. Panagiotopoulos, R. Ronsley, D. Elbe, J. Davidson, and D.H. Smith, First do no harm: promoting an evidence-based approach to atypical antipsychotic use in children and adolescents. J. Can. Acad. Child Adolesc. Psychiatry 19 (2010) 124-137.
- [2] D.J. Posey, K.A. Stigler, C.A. Erickson, and C.J. McDougle, Antipsychotics in the treatment of autism. J. Clin. Invest 118 (2008) 6-14.
- [3] P. Pramyothin and L. Khaodhiar, Metabolic syndrome with the atypical antipsychotics. Curr. Opin. Endocrinol. Diabetes Obes. 17 (2010) 460-466.
- [4] N.M. Richtand, J.A. Welge, A.D. Logue, P.E. Keck, Jr., S.M. Strakowski, and R.K. McNamara, Dopamine and serotonin receptor binding and antipsychotic efficacy. Neuropsychopharmacology 32 (2007) 1715-1726.
- [5] P. Seeman, Atypical antipsychotics: mechanism of action. Can. J. Psychiatry 47 (2002) 27-38.
- [6] D.C. Borcherding, E.R. Hugo, G. Idelman, N.W. Richtand, J. Loftus, and N. Ben-Jonathan, Dopamine receptors in human adipocytes: expression and functions. PLoS. One. 6 (2011) e25537.
- [7] American Psychiatric Association, Practice guide for the treatment of patients with schizophrenia. American Psychiatric Association 1 (1997) 1-20.
- [8] J. Ferno, S. Skrede, A.O. Vik-Mo, G. Jassim, H.S. Le, and V.M. Steen, Lipogenic effects of psychotropic drugs: focus on the SREBP system. Front Biosci. 16 (2011) 49-60.
- [9] C. Lara-Castro, Y. Fu, B.H. Chung, and W.T. Garvey, Adiponectin and the metabolic syndrome: mechanisms mediating risk for metabolic and cardiovascular disease. Curr. Opin. Lipidol. 18 (2007) 263-270.
- [10] N. Ben-Jonathan and R. Hnasko, Dopamine as a prolactin (PRL) inhibitor. Endocr. Rev. 22 (2001) 724-763.
- [11] T. Kelesidis, I. Kelesidis, S. Chou, and C.S. Mantzoros, Narrative review: the role of leptin in human physiology: emerging clinical applications. Ann. Intern. Med. 152 (2010) 93-100.
- [12] E. Elinav, L. Niv-Spector, M. Katz, T.O. Price, M. Ali, M. Yacobovitz, G. Solomon, S. Reicher, J.L. Lynch, Z. Halpern, W.A. Banks, and A. Gertler, Pegylated leptin antagonist is a potent orexigenic agent: preparation and mechanism of activity. Endocrinology 150 (2009) 3083-3091.
- [13] M. McFarland-Mancini, E. Hugo, J. Loftus, and N. Ben-Jonathan, Induction of prolactin expression and release in human preadipocytes by cAMP activating ligands. Biochem. Biophys. Res. Commun. 344 (2006) 9-16.
- [14] E.R. Hugo, T.D. Brandebourg, C.E. Comstock, K.S. Gersin, J.J. Sussman, and N. Ben-Jonathan, LS14: a novel human adipocyte cell line that produces prolactin. Endocrinology. 147 (2006) 306-313.

1		Dopamine and Serotonin Receptors in Human Adipocytes:
2		Do they Mediate Adverse Metabolic Effects of Antipsychotics?
3	]	Eric R. Hugo, Dana C. Borcherding, Neil M. Richtand, and Nira Ben-Jonathan
4 5	Depart	ments of Cancer and Cell Biology (ERH, DCB, NBJ), and Psychiatry and Behavioral Neuroscience (NMR)
6		University of Cincinnati, Cincinnati Ohio 45267, USA
7		
8 9 10 11	Correspondin	ng Author: Ben-Jonathan, N. (Nira.Ben-Jonathan@uc.edu)
12 13	Keywords:	dopamine receptors, serotonin receptors, human adipocytes, atypical antipsychotics, weight gain, metabolic syndrome, psychiatric dysfunctions

# 1 Abstract

2

3 Atypical antipsychotics (AAP) are used to treat millions of patients with schizophrenia, bipolar disorder, 4 depression, posttraumatic stress disorder, and autism. Although effective in ameliorating many 5 psychiatric symptoms, AAP also induce substantial weight gain and other metabolic disturbances. The 6 overarching consensus is that they do so by acting on brain dopaminergic (DAR) and serotonergic (5-7 HTR) receptors. We challenge this dogma by reviewing evidence that adipose tissue, via endogenous 8 DAR and 5-HTR, is a major target of AAP. This model underscores peripheral actions of AAP which 9 complement, or override, their central actions. This knowledge should serve as a guide for the rational 10 selection of existing drugs, and as a benchmark for developing a new generation of drugs devoid of 11 adverse metabolic side-effects.

#### 1 The issue of metabolic disturbances by atypical antipsychotics

2 AAP are composed of a group of medications with high affinity binding to dopamine (DAR) and 3 serotonin (5-HTR) receptors, that are used to treat a steadily growing list of psychiatric disorders. In 4 2004, four scientific societies: American Diabetes Association, American Psychiatric Association, 5 American Association of Clinical Endocrinologists, and The Obesity Society, convened a consensus 6 development conference on AAP evaluation [1]. The panel concluded that although AAP have lower 7 neurological side-effects than conventional antipsychotics, their association with dramatic weight gain, 8 diabetes and an atherogenic lipid profile has become a major public health concern with great economic 9 impact. The panel emphasized the need for elucidating the mechanism by which AAP exert their adverse 10 metabolic effects.

Presently, a clear understanding of the receptors and/or anatomical sites that mediate the metabolic side effects of AAP has not emerged. The general consensus is that AAP bind differentially to DAR and 5-HTR subtypes, but also to some adrenergic, histaminergic and cholinergic receptors [2-4], albeit with much uncertainty as to the most critical receptor(s) targeted by each drug. There is also no agreement with respect to their sites of action within the brain, implicating mesolimbic, mesocortical, and nigrostriatal dopaminergic pathways, all of which have multiple interactions with other neurotransmitters and neuropeptides.

18 While not disputing the therapeutic effects of AAP on the brain, our main premise is that adipose 19 tissue, via endogenous DAR and 5-HTR subtypes, mediates many metabolic actions of AAP (Figure 1). 20 We propose that AAP-induced suppression of leptin stimulates food intake and weight gain, while 21 inhibition of adiponectin and stimulation of pro-inflammatory cytokines exacerbate the metabolic 22 syndrome. AAP may also increase adiposity by augmenting the differentiation of preadipocytes into 23 mature adipocytes (adipogenesis), and/or by enhancing their lipid accumulation. To lay the foundation 24 for this premise, we review metabolic dysregulation by AAP and discuss adipose functions known to be 25 affected by AAP such as adipogenesis, lipogenesis/lipolysis and production of key adipokines. We then 26 present data on the expression and functions of DAR and 5-HTR subtypes in adipocytes, evaluate clinical 27 data and animal studies on AAP actions on adipose functions, and discuss the implications of this 28 knowledge for the future development of improved antipsychotics.

29

#### **30** Antipsychotic medications

#### 31 Conventional and atypical antipsychotics

32 The dopamine (DA) theory of schizophrenia was based on the observations that drugs that effectively

33 increase DA in certain brain areas caused schizophrenic-like symptoms, while blockade of DA actions

ameliorated such symptoms [5]. DA is a catecholamine which binds to five receptors, classified by 1 2 structure, pharmacology and function into  $D_2R$ -like ( $D_2R$ ,  $D_3R$  and  $D_4R$ ) and D1R-like ( $D_1R$  and  $D_5R$ ) 3 receptors [6,7]. Serotonin (5HT) is an indoleamine which binds to seven classes of 5-HTR and is 4 implicated in the pathophysiology of depression, anxiety and schizophrenia, as well as in obsessive-5 compulsive and eating disorders [8]. Conventional antipsychotics, e.g., chloropromazine, haloperidol 6 and perphenazine, act primarily as D2R antagonists and ameliorate positive symptoms of psychosis. 7 However, their tolerability is limited by neurological side effects such as Parkinsonism, akathisia and 8 tardive dyskinesia [9]. The search for drugs with lower extrapyramidal side effects led to the 9 development of 'atypical' antipsychotics, or AAP, which maintain high affinity binding to D<sub>2</sub>R, but also 10 have high affinity binding to serotonin 5HT<sub>2A</sub>R [10]. Box 1 lists the various mental disorders, i.e., 11 schizophrenia, bipolar disorder, major depression, posttraumatic stress disorder, and autism [11,12], 12 which are currently treated with AAP.

13

# 14 Metabolic side effects of AAP

15 The initial optimism with regard to the tolerability of AAP has been tempered by serious metabolic 16 disturbances [13-15]. Excessive weight gain and changes in serum lipids, adipokines and inflammatory 17 cytokines in response to AAP are well documented in both adults and pediatric patients. A case in point 18 is a recent report on the effects of AAP in 272 youth, aged 4 to 19 years, diagnosed with schizophrenia, 19 bipolar disorder and autism [16]. Although most drugs improved behavioral problems, they came at the 20 expense of substantial weight gain. Within 10-12 weeks of treatment, the mean weight gain was 8.5 kg 21 for olanzapine (Zyprexa), 6.1 kg for quetiapine (Seroquel), 5.3 kg for risperidone (Risperdal), and 4.4 22 kg for aripiprazole (Abilify), as compared to 0.2 kg in untreated controls. Hyperlipidemia and insulin 23 resistance were also seen. Children are especially vulnerable to early weight gain, as it increases the risks 24 for developing the metabolic syndrome in adulthood [17]. As depicted in Table 1, among the various 25 AAP in current practice, olanzapine and clozapine carry the greatest risk of weight gain, diabetes and 26 dyslipidemia, quetiapine and risperidone carry an intermediate risk, while ziprasidone and aripiprazole 27 confer the lowest risk [1,18].

### 28 Key features of adipose tissue and adipocytes

# 29 Adipose tissue composition and distribution

The most abundant cell type within adipose tissue is the large, lipid filled adipocyte, with a small number of proliferation-competent preadipocytes. The stroma also contains endothelial cells, pericytes, mast cells, fibroblasts, nerve endings, and immune cells. Two types of adipocytes are recognized: brown and white. Brown adipocytes have a major role in thermogenesis and are most abundant in neonates. White adipocytes are segregated into discreet anatomical depots, i.e., visceral and subcutaneous, with a clear sexual dimorphism in their distribution [19]. The depots differ in the expression of several receptors, responsiveness to circulating and local regulators, and lipolytic activity [20,21]. Excess abdominal fat is the major contributor to obesity-related metabolic disorders (Box 2).

6

# 7 Adipogenesis

8 Obesity results from increased adipocyte size (hypertrophy) and number (hyperplasia). Fat cell number 9 is primarily determined by adipogenesis, a terminal differentiation process which takes 10-14 days and 10 results in the conversion of preadipocytes into mature adipocytes. Preadipocytes are fibroblast-like 11 unipotent cells that are 'committed' to the adipocyte lineage [22]. Adipogenesis proceeds in several 12 intertwined steps which begin with an initial growth arrest followed by clonal expansion and the 13 initiation of differentiation. The early stages of adipogenesis are characterized by coordinated waves of 14 expression of several transcription factors, extracellular matrix and cytoskeletal proteins, whereas the 15 later stages are denoted by increased expression of lipogenic enzymes and adipokines [23].

16

# 17 Lipogenesis and lipolysis

18 Lipogenesis encompasses the processes of fatty acid synthesis and production of triglycerides by 19 esterification of fatty acids with glycerol. Lipolysis is the process by which lipids are broken down step-20 wise into free fatty acids (FFA) and glycerol. Catecholamines, acting via  $\beta$ -adrenergic receptors ( $\beta$ -AR) 21 are the most potent lipolytic hormones, while insulin is a potent anti-lipolytic hormone [24]. Notably, 22 norepinephrine (NE), but not selective  $\beta$ 1- or  $\beta$ 2-AR agonists, was still capable of stimulating lipolysis 23 in triple ( $\beta 1/\beta 2/\beta 3$ ) AR-knockout mice [25]. As there is no identified fourth  $\beta$ -AR, the authors proposed 24 that the lipolytic activity of NE in the β-less adipocytes was due to an unknown Gs-protein-coupled 25 receptor with low affinity for NE. Alternative explanation is the possibility that NE at high 26 concentrations binds DAR [6].

### 27 Selected adipokines

Leptin is a key adipokine which regulates food intake and energy expenditure. In humans, leptin administration reduces appetite while its chronic deficiency causes extreme obesity; leptin production is proportional to adipose tissue mass [26,27]. Adiponectin is a potent adipokine which protects against the metabolic syndrome [28,29]. It has insulin-sensitizing, anti-inflammatory and anti-atherogenic properties, with weight reduction accompanied by increased serum adiponectin levels and improved insulin sensitivity. IL-6 is a pro-inflammatory cytokine which contributes to the low level of
inflammation associated with obesity. Elevated serum IL-6 increases the production of c-reactive protein
and can lead to coronary heart disease and atherosclerosis [30]. Within adipose tissue, IL-6 is mainly
produced by macrophages and preadipocytes and to a lesser extent by mature adipocytes [31].

5

# 6 The dopaminergic system in adipocytes

# 7 Sources of dopamine to the adipocytes

8 DA synthesis is regulated by the rate limiting step tyrosine hydroxylase (TH). Whereas most studies 9 have focused on DA production and release within the brain, the rather large concentrations of DA, 10 primarily as DA-sulfate (DA-S), in the human circulation have been largely ignored. As illustrated in 11 Figure 2, peripheral DA originates from the gastrointestinal (GI) tract, spleen, paraganglia, and adrenal 12 medulla [32,33]. Ingestion of a meal in fasting individuals causes a 50-fold rise in circulating DA-S 13 levels. Under basal conditions, serum DA-S at  $\approx 5$  ng/ml exceeds the combined levels of free DA (0.3) 14 ng/ml), NE (0.2 ng/ml) or epinephrine (0.05 ng/ml). Adipose tissue can also receive DA input from 15 adjacent mesenteric neurons and paraganglia, as well as from lymphocytes and macrophages which 16 accumulate in fat and can produce DA [34,35].

17 Although DA-S comprises >95% of serum DA, it escapes detection by most analytical methods. 18 Sulfoconjugation is done in the liver, GI tract and platelets by SULT1A3 sulfotransferase. In humans, a 19 single amino acid substitution confers the enzyme with higher affinity for DA than NE or epinephrine 20 [36]. Unlike the irreversible DA inactivation by deamination, O-methylation or glucoronidation, sulfo-21 conjugation is reversible, and DA-S can be converted to DA by arylsulfatase A (ARSA), a releasable 22 lysosomal enzyme [37,38]. ARSA is expressed in human adipose tissue and its activity increases after 23 adipogenesis [39]. Although DA-S does not activate DAR, when incubated with human adipocytes, its 24 activity is indistinguishable from that of DA, suggesting that adipocytes can de-conjugate DA-S to DA 25 [39]. Given that DA-S has an half-life of 4.5 hrs, as compared to a few minutes for free DA [40], DA-S 26 may serve as a stable reservoir of bioactive DA to adipose tissue (see Figure 2).

27

#### 28 Expression of dopamine receptor subtypes

DAR are made of a single polypeptide chain, ranging in size from 387 to 475 residues. Each receptor is composed of seven transmembrane spanning helices that form a hydrophobic ligand-binding pocket. The D1R-like genes have no introns whereas the  $D_2R$ ,  $D_3R$  and  $D_4R$  have 6, 5, and 3 introns, respectively [6]. The presence of introns enables the generation of receptor variants by alternative splicing. Some variants have distinct anatomical, physiological, and pharmacological properties [41]. The ability of DAR to couple to several G-proteins is at the heart of their action. The D2R-like are coupled to Gαi and Gαo proteins and inhibit adenylate cyclase (AC), whereas the D1R-like are coupled to Gαs, Gαolf or Gαq proteins, and stimulate AC and PKA, but can also activate phospholipases (e.g., PLC) as well as the MAPK and PI3K/Akt pathways [7,42]. With the exception of D3R, all DAR are expressed in human adipose tissue, primary adipocytes and two human adipocyte cell lines, LS14 and SW872, at both the RNA and protein levels [39]. An older study described D1R-like in brown rat adipocytes [43], but there are no comparable data on brown human adipocytes.

8 DA signals through several pathways in human adipocytes. For instance, at low nM doses, DA 9 suppresses cAMP in differentiated LS14 adipocytes, but increases cGMP at higher doses. DA also 10 rapidly activates the MAPK system but has little effect on Akt signaling [39]. The binding affinity of 11 DA to DAR ranges from 50 nM for  $D_3R$  to >2  $\mu$ M for  $D_1R$  [6], underscoring the variable response to 12 DA by cells that express more than one receptor subtype. Indeed, DA exhibits a non-monotonic, U-13 shaped activity curve on several molecular targets in human adipocytes [39]. This suggests that 14 activation of inhibitory DAR at low DA concentrations is counteracted by activation of stimulatory DAR at higher concentrations, resembling the opposite regulation of lipolysis by  $\propto$  and  $\beta$  adrenergic 15 16 receptors [24]. Less ambiguity should results from the use of selective DAR agonists and antagonists 17 in combination with targeted DAR knockdown.

### 18 *Putative functions*

19 The expression of D2R increases, while that of D1R decreases, during the first few days of human 20 preadipocyte differentiation [39], raising the possibility that they participate in some manner in 21 adipogenesis. A search using the Genomatic Matinspector program (http://www.genomatix.de/online) 22 identified a putative PPARy binding site in the promoters of  $D_1R$  and  $D_2R$ , while the  $D_1R$  promoter also 23 has a C/EBP binding site. Given that these transcription factors play critical roles in the initiation and 24 progression of adipogenesis [23], DAR may be among their regulated genes. The use of selective DAR 25 agonists and antagonists revealed that DA acts via D<sub>2</sub>R to inhibit adipocyte PRL expression and release 26 while the  $D_1R/D_5R$  appear to mediate the suppression of leptin release and the stimulation of adiponectin 27 and IL-6 release [39]. Locally-produced PRL has multiple roles in adipose functions, including 28 stimulating of adipogenesis, inhibition of lipolysis and variable effects on adipokine release [44]. 29 Notably, short term treatment of obese women with bromocriptine, a D<sub>2</sub>R agonist, resulted in increased 30 serum FFA levels and suppressed leptin [45], indicating either a direct or an indirect effects of DA on 31 lipolysis and leptin release. Results from our laboratory (Hugo et al, unpublished) show direct lipolytic 32 effects of low nM doses of DA on cultured human adipocytes.

#### 1 The serotonergic system in adipocytes

# 2 Sources of serotonin to the adipocytes

3 Serotonin is synthesized from 5-hydroxytryptophan by tryptophan hydroxylase (TPH), a rate limiting 4 enzyme which exists in two isoforms: peripheral TPH1, and brain-specific TPH2 [46]. Over 95% of 5 peripheral serotonin is synthesized by the enterochromaffin cells within the GI tract [47]. After its 6 release, serum serotonin is rapidly taken up by platelets via the serotonin transporter (SERT), and is 7 sequestered into dense granules by vesicular monoamine transporters [48]. Platelets activation can result 8 in release of serotonin which then becomes available to various tissues. Adipocytes also have the 9 capacity for *de-novo* synthesis of serotonin (see Figure 2). Both 3T3-L1 murine adipocytes [49] and 10 visceral rat adipocytes [50] express TPH1, and are capable of storing and releasing serotonin.

#### 11 Expression of serotonin receptor subtypes

The 5-HTR are grouped into seven sub-classes comprised of 14 distinct receptors. With the exception of 5-HT<sub>3</sub>R which gate an ion channel, all others are G-protein-coupled receptors that activate second messengers such as AC, PLC and PKA and result in excitatory or inhibitory responses [51]. As illustrated in Table 1, the general consensus is that some AAP act by blocking 5-HT<sub>2A</sub>R, stimulating 5-HT<sub>1A</sub>R, and variably binding to 5-HT<sub>2C</sub>R, 5-HT<sub>6</sub>R or 5-HT<sub>7</sub>R [52]. A cross-talk between serotonergic and dopaminergic receptors and their downstream signaling pathways [4] can alter antipsychotic effectiveness, metabolic disturbances, and neurological adverse effects of each drug.

Most 5-HTR subtypes are expressed in peripheral organs where they participate in the regulation of cardiovascular and respiratory functions, bowel motility, ejaculatory latency and bladder control [8]. Expression of the following 5-HTR: 1A, 1B, 1D, 1F, 2A, 2C, 5A, 5B, 6 and 7 have been detected in 3T3-L1 adipocytes, with expression of 2C receptors increasing, and 2<sub>A</sub> receptors decreasing, during cell differentiation [49]. As evident at both the gene and protein levels, visceral rat adipocytes express 2A, 2B and 2C [50]. Studies in our laboratory (E. Hugo et al., unpublished) confirmed expression of 1A, 2A, 2B, and 7 serotonin receptor subtypes in primary human adipocytes and LS14 adipocytes.

26

#### 27 *Putative functions*

Peripheral serotonin administration affects glucose and lipid metabolism [53,54], but only limited data are available on the direct effects of serotonin on the adipocytes. One study reported a rapid, biphasic inhibition of leptin expression and release from cultured primary rat adipocytes by serotonin [50]. Another study found that selective 5-HT<sub>2A</sub>R and 5-HT<sub>2C</sub>R antagonists inhibited 3T3-L1 cell differentiation, with similar effects achieved by overexpression of micro-RNA(miR)-448 which targets 5-HT<sub>2C</sub>R [49]. A recent paper reported that treatment of 3T3-L1 adipocytes with serotonin inhibited
 insulin-stimulated glucose uptake via the transactivation of the EGF receptor and the ERK1/2-mTOR
 pathway, but did not identify the 5-HTR involved [55].

4

#### 5 Effects of atypical antipsychotics on adipocyte functions

# 6 Clinical data

7 Treatment of patients with AAP, especially olanzapine and clozapine, is accompanied by rapid increases 8 in appetite and caloric intake [56-58]. Appetite is controlled by a network of hypothalamic and extra-9 hypothalamic neurons that are modulated by hormones from the stomach (ghrelin), pancreas (insulin), 10 and adipose tissue (leptin), and are also affected by circulating glucose and lipid levels [59]. Given that 11 leptin is a major satiety hormone, it stands to reason that drugs which increase appetite are associated 12 with suppressed leptin. Yet, most studies reported elevated serum leptin levels in response to weight-13 inducing AAP [60]. Close examination of these data reveals that leptin was determined after weeks or 14 months of drug treatment, suggesting that the observed rise in serum leptin is secondary to increased fat 15 tissue mass. Because appetite is regulated at much shorter time intervals, data on acute effects of AAP 16 on serum leptin would be highly informative, but are scarce and inconclusive [57,61]. Clearly, a 17 functional link between AAP, circulating leptin, hyperphagia, and weight gain warrants a close 18 examination. As it is not feasible to rapidly suppress leptin independent of food intake, or reversibly 19 block its actions in human subjects, animal models are needed.

20 Elevated FFA flux from adipose tissue amplifies many of the metabolic derangements that underlie 21 obesity-associated insulin resistance. However, the reports on serum FFA levels following treatments 22 with AAP are inconsistent, with some observing marked increases [62], while others finding no changes 23 or a decline [63,64]. A large study with 567 schizophrenic patients treated with clozapine, olanzapine 24 and risperidone, found lower serum adiponectin levels [65], while others found no change [60]. 25 Treatment of patients with clozapine increased serum IL-6 within one week [66], whereas chronic 26 treatment with risperidone was ineffective [67]. The discrepancies among the above studies undoubtedly 27 reflect the use of different drugs, variable doses, different length of treatment, and a non-standardized 28 time of blood sampling relative to food intake. Furthermore, clinical studies cannot resolve whether the 29 observed drug effects are due to their direct or indirect actions on adipose tissue.

30

#### 31 Animal studies

Both mice [68] and rats [69] have been used as acceptable, albeit imperfect, animal models for studying the metabolic side effects of AAP. A major advantage of using rats is their larger blood volume for sampling, and a more sizable adipose tissue. Treatment of female rats with olanzapine increased food intake, body weight and fat deposits within one week, and elevated serum ghrelin levels while reducing circulating insulin within two weeks [69]. Acute changes in response to AAP were also reported, with oral administration of olanzapine stimulating food intake within 24 hrs and increasing weight gain within 2-3 days [70,71]. Importantly, within 5 hrs of ip injection of olanzapine, plasma leptin was reduced by 50%, the glucose-induced leptin rise was blunted, and ghrelin was suppressed. The authors concluded that acute hypoleptinemia is a major contributor to AAP-induced hyperphagia, but cautioned that more data are needed to substantiate this postulate.

8 Chronic treatment of rats with AAP induces several biochemical and cellular alterations in adipose 9 tissue, including decreased expression of hormone sensitive lipase and enhanced expression of fatty acid 10 synthase [72,73]. The combined effect of suppression of lipolysis and augmented lipogenesis resulted in 11 fat accumulation and enlargement of the adipocytes. As drug usage *in vivo* cannot distinguish between 12 central vs peripheral actions, data obtained with isolated adipocytes are critical. Indeed, AAP enhanced 13 triglyceride storage by upregulating the lipogenic enzymes and reducing lipolysis in cultured rat and 14 murine adipocytes [74,75]. The drugs also impaired insulin-stimulated glucose uptake. These reports 15 indicate that AAP can directly stimulate lipid accumulation and alter the size of adipocytes, but did not 16 address their mechanism of action. Studies in our laboratory (Hugo et al unpublished) found that several 17 AAP directly suppressed leptin and adiponectin and stimulated IL-6 release as well as increased lipolysis 18 from human adipocytes.

19

21

# 20 Concluding remarks

22 The dramatic worldwide epidemics of obesity and diabetes has attracted significant attention to the 23 central role played by adipose tissue in metabolic homeostasis and its dysregulation. The last few decades 24 have witnessed a remarkable pace of discovery of transcription factors that regulate adipogenesis, 25 enzymes that regulate lipid assembly and breakdown, and adipose-secreted factors that regulate brain, 26 cardiovascular and hepatic functions (Box 2). One of the objectives of this review was to underscore 27 the emerging knowledge on the impact of dopaminergic and serotonergic receptors on adjocyte biology, 28 while recognizing the need for more information on the identity of the receptor subtypes involved and 29 their full spectrum of actions.

Antipsychotic medications have become a mainstay of treatment for a steadily growing list of mental disorders. Of particular concern is the increased exposure of pediatric patients at higher risks for metabolic disturbances. Unquestionably, many patients do benefit from AAP medications in ameliorating psychiatric symptoms, except that these benefits are often diminished by severe metabolic side effects that increase mortality risk from cardiovascular disease. The overarching consensus in this

1 field is that drug actions are confined to the brain. Although previous studies showed drug effects on 2 typical pancreatic, liver and adipose tissue functions, most of these effects were ascribed to indirect drug 3 actions on peripheral organs via brain-derived mechanisms. Based on animal experimentation and 4 studies with isolated adipocytes, but not yet supported by extensive clinical data, we offer a working 5 model which implicates direct actions of AAP on adipose tissue which complement, or override, their 6 central actions. The model emphasizes three major components: AAP-induced changes in leptin which 7 increase appetite, alterations in adipokines/cytokines which exacerbate the metabolic syndrome, and 8 changes in adipocyte differentiation and/or lipid accumulation which augment adiposity.

9 The proposed model stipulates that acute suppression of leptin by AAP stimulates appetite, increases 10 food intake and results in weight gain. However, following chronic treatment with AAP, the expanding 11 fat mass leads to hyperleptinemia and the development of leptin resistance. Presumably, an initial rapid 12 weight gain induced by acute suppressions of leptin by AAP eventually levels off because of the lower 13 ability of elevated leptin to suppress appetite as a consequence of altered responsiveness of brain 14 orexigenic/anti-orexigenic circuits to leptin. Granted, this concept is oversimplified because it does not 15 incorporate other appetite regulating factors such as glucose, insulin, ghrelin and PYY, as well as AAP-16 induced activation of brain DAR/5-HTR which impinge on appetite regulating neurons [76,77]. 17 Nonetheless, the focus on leptin serves as a reasonable starting point for assessing the role of adipose-18 derived adipokines as mediators of AAP-induced weight gain. Future clinical studies which compare 19 acute vs chronic changes in leptin and weight gain in response to AAP treatment are critical for testing 20 this concept.

Weight gain is the most obvious side effect of AAP, but more subtle effects should be taken into account. A given drug can alter the endocrine functions of adipose tissue, its lipid storage capacity or both. Changes in adipokine release can affect insulin resistance (i.e., adiponectin) or cardiovascular functions (i.e., pro-inflammatory cytokines). Notably, drug-induced changes in adipokine release can occur without a major weight gain. Again, clinical studies which take into account both drug doses and timing of blood sampling with respect to food intake on circulating cytokines should be undertaken.

Because clinical studies cannot effectively address the mechanism of drug actions, studies with animals that afford invasive procedures, as well as the use of genetically-modified animals, can fill the gaps. Yet, the control of metabolic homeostasis as well as drug responsiveness can differ between rodents and humans. A case in point is an obvious sexual dimorphism in AAP-induced weight gain in rats, i.e. females are more sensitive to AAP-induced adiposity than males, which is not apparent in humans. Additional pharmacological and biochemical studies with isolated human adipocytes or adipocyte cell lines would be required to establish which DAR and 5-HTR subtypes are targeted by each drug. Again, the limitations of this approach in terms of their extrapolation to the behavior of an intact
 adipose tissue should be recognized.

3 There is a good opportunity for future intervention aimed at finding drugs with little or no metabolic 4 side effects. Once the full spectrum of drug actions on the adipocytes is delineated, practical means for 5 identifying drugs that do, or do not, inflict metabolic disturbances can be devised. We foresee that the 6 creation of a 'metabolic signature' could serve as a benchmark for developing new drugs devoid of 7 undesirable metabolic side effects. Given the millions of patients worldwide that are chronically treated 8 with antipsychotics, many pharmaceutical companies are actively engaged in the development of new 9 drugs in this class. Human adipocytes could be easily integrated into the screening paradigms of 10 candidate new drugs for an early identification of potential adverse metabolic activities prior to costly 11 animal experimentation and prolonged and expensive clinical trials.

12

14

# 13 Acknowledgements

This work was supported by NIH grants ES012212 and CA096613, DOD BC05725 and AR110050,
Susan G. Komen grant BCRT87406, and a grant from the Elsa U Pardee foundation (to NBJ), NIH
training grant CA117846 (to DCB), and a grant by the Department of Veterans Affairs Medical Research
Service (to NMR).

# 19 Conflicts

N. Richtand has the following disclosures: Speaker's Bureau: Bristol-Meyers Squibb, Schering-Plough
 Corporation, Novartis Pharmaceuticals, Sunovion Pharmaceuticals Inc. Consultant: Bristol-Meyers
 Squibb, Sunovion Pharmaceuticals Inc. Grant/Research Support: Ortho-McNeil Janssen Scientific
 Affairs, LLC, AstraZeneca Pharmaceuticals.



Figure 1



Figure 2

# Figure Legends 2

- 3 The role of adipose tissue in mediating metabolic disturbances by atypical Figure 1: 4 antipsychotics (AAP). Acting via dopamine and serotonin receptors on the adipocytes, 5 AAP accelerate adipogenesis and stimulate lipid accumulation, resulting in fat mass 6 expansion. Acute suppression of leptin by AAP leads to increased appetite and weight gain, 7 whereas a reduction in circulating adiponectin leads to insulin resistance. The metabolic 8 syndrome, which involves target tissues such as liver, pancreas and the cardiovascular 9 system, is further exacerbated by AAP-induced increases in circulating free fatty acids and 10 inflammatory cytokines. Activation of neuronal circuits in the brain by AAP directly affect 11 the regulation of food intake, and indirectly affect adipose tissue functions via the 12 sympathetic nervous system.
- 13
- 14 Figure 2: Sources and actions of dopamine (DA) and serotonin (5HT) on the adipocyte. Sources 15 of DA include the GI tract, peripheral nerves, paraganglia and immune cells. DA primarily 16 circulates as a metabolically inactive sulfated form (DA-S), but can be deconjugated to 17 bioactive DA by aryl sulfatase A (ARSA), a secretable lysosomal enzyme. DA can bind to 18 either  $D_2R$ -like or to  $D_1R$ -like receptors and activate a variety of signaling pathways which 19 culminate in alterations in lipogenesis, lipolysis, adipogenesis and adipokine release. 20 Serotonin (5HT) input to the adipocytes comes primarily from the GI tract via circulating 21 platelets. Adipocytes can also synthesize serotonin *de novo* from tryptophan (Trp) by 22 peripheral tryptophan hydroxylase. Serotonin can bind to a number of receptor (5-HTR) 23 subtypes and affect similar parameters as does DA. Whether the simultaneous activation of 24 DAR and 5-HTR by any given drug results in augmentation, synergism or antagonism in 25 each of the putative functions remains unclear.

1 Glossary

2

Adiponectin: a 30 kDa protein produced by adipocytes which circulates as high and low molecular
 weight isoforms, and its serum levels are inversely related to adiposity. Adiponectin reduces insulin
 resistance, inflammation, and atherosclerosis.

6 Adrenergic receptors: a class of G-protein-coupled receptors, divided into two main subtypes,  $\alpha$  and  $\beta$ , 7 which bind the catecholamines norepinephrine and epinephrine. These receptors are involved in many 8 functions, including fight or flight response, lipolysis, smooth muscle contraction, heart rate, and 9 vasoconstriction.

Arylsulfatase A (ARSA): a secretable lysosomal enzyme that can convert the inactive dopamine-sulfate
 back into bioactive dopamine by removing the sulfate group.

12 Extrapyramidal Side Effects: movement disorders such as akinesia (decreased voluntary movement),

pseudoparkinsonism and akathisia (feeling of restlesness) often resulting from the use of dopamine
 antagonists (neuroleptic drugs).

15 Free fatty acids (FFA): carboxylic acids with a long aliphatic tail that is not attached to other molecules.

16 Usually derived from triglycerides, they are a source of energy for peripheral tissues.

G-protein-coupled receptors (GPCR): a large superfamily of seven-transmembrane receptors that
activate G-proteins when bound to a ligand.

Ghrelin: a 28 kDa protein hormone produced by the stomach which stimulates hunger. Ghrelin levelsdecrease in the fed state and increase with fasting.

Interleukin-6 (IL-6): a 22 kDa inflammatory cytokine produced by preadipocytes and macrophages in adipose tissue, which increases c-reactive protein production and heart disease. Plasma levels of IL-6 correlate with BMI and the size of adipocytes.

Leptin: a 16 kDa protein hormone produced primarily by adipocytes. Leptin functions as an energy sensor in the hypothalamus by inhibiting appetite and stimulating energy expenditure. Leptin knockout mice (ob/ob) are hyperphagic and obese. However, in humans leptin levels increase with obesity.

Lipogenesis: the process by which acetyl-CoA is converted into lipids, which allows for the efficient
storage of energy.

29 Lipolysis: the process by which triglycerides are hydrolyzed to FFA and glycerol. The breakdown of

30 lipids allows for their mobilization and use as energy for other tissues, and results in a reduction in lipid

31 droplet size and overall adipose tissue mass.

32 **Tryptophan hydroxylase (TPH):** the rate-limiting enzyme for the synthesis of serotonin from 33 tryptophan. TPH2 is the brain-specific isoform, while TPH1 is found in multiple peripheral tissues.

# 1 **Box 1. Therapeutic use of antipsychotic medications: Past and present** 2

3 Chlorpromazine, the first phenothiazine antipsychotic medication, was developed as an adjuvant to 4 anesthetics [78]. The recognition in the early 1950s of its antipsychotic efficacy resulted in the liberation of thousands of institutionalized patients from insane asylums. Indeed, U.S. state mental hospitals 5 6 housed 560,000 patients in 1955, but less than 80,000 patients by 1999. The discovery of clozapine in 7 1958 identified the improved neurological side effect profile of "atypical" antipsychotics (AAP), with a lower incidence of dystonia, parkinsonism, akathisia, and tardive dyskinesia compared to "typical" 8 9 antipsychotics [79]. However, the association between clozapine and agranulocytosis has limited its 10 therapeutic usage to treatment-resistant schizophrenia. In contrast, the lower neurological side effects of 11 the subsequently developed AAP resulted in an exponential increase in their use, and they now account 12 for 5% of U.S. drug expenditures [80]. FDA-approved indications for AAP include: schizophrenia, 13 bipolar mania and mixed state, adjunctive treatment for major depression, irritability associated with 14 autism, Tourette Syndrome, and bipolar depression. Yet, almost two-thirds of prescriptions for 15 antipsychotic medications are for 'of label' non-FDA approved indications, including agitation in 16 delirious patients, psychosis and agitation secondary to dementia, symptoms of post-traumatic stress 17 disorder, personality disorder, attention deficit hyperactivity disorder, anxiety and insomnia [77].

# 1 Box 2. Obesity, the metabolic syndrome, and adipose tissue homeostasis.

- Obesity is one of the most challenging health problems of the 21<sup>st</sup> century. More than 60% of
   the US population is overweight (body mass index or BMI >25), with half of those individuals
   classified as obese (BMI>30).
- Obesity (increased adiposity) results from an imbalance between food intake and energy
   expenditure.
- The most common health complications associated with obesity are cardiovascular disease
   (hypertension, atherosclerosis, and coronary artery disease), the metabolic syndrome, and type II
   diabetes.
- As defined by the International Diabetes Federation, the metabolic syndrome is central (abdominal/visceral) obesity with any two of the following conditions: elevated serum triglycerides, reduced high density lipoprotein (HDL) cholesterol, hypertension, or impaired glucose tolerance.
- The metabolic syndrome is developed, in part, from disturbances of adipose tissue homeostasis,
   including increased release of inflammatory cytokines and free fatty acids, as well as decreased
   release of protective adipokines.
- Inflammatory cytokines consist of, but are not limited to, interleukin (IL)-1β, IL- 6, monocyte
   chemotactic protein-1 (MCP-1), and tumor necrosis factor α (TNFα). These cytokines are major
   contributors to cardiovascular impairments associated with the metabolic syndrome.
- Protective adipokines such as adiponectin increase insulin sensitivity. Their suppression during
   the metabolic syndrome contribute to insulin resistance and can lead to the development of
   diabetes.

Drug <sup>a</sup>		receptors <sup>b</sup>			Metabolic effects		
generic trade®		DAR	5-HTR	other	weight	IR	Refs <sup>c</sup>
1 <sup>st</sup> generation High DAR affinity Haloperidol	Haldol	2>4>3>1>5	2A>1B>7	H1	=/+	II	[2,52,81-83]
Med. DAR affinity Perphenazine	Trilafon	2~3>4	2A~2B>2C~6~7>1F~1 A>3>1B>1e>1D>5A	H1	=	=	[2,82,83]
Low DAR affinity Chlorpromazine	Thorazine	2~3>4>1>5	2A>2C~6~7>1e>1D	H1,A2	++++	$\uparrow$	[81-83]
2 <sup>nd</sup> generation Asenapine	Saphris	1~2~3~4	1A~1B~2A~2B~2C~7	H1,A1,A2	+	nr <sup>d</sup>	[84]
Clozapine	Clozaril	4>1>2>3	2A~2B>2C~6~7>1F~1 A>3>1B>1e>1D>5A	H1, <mark>M1</mark> ,A1	+++	$\uparrow$	[2,52,81,82]
Iloperidone	Fanapt	2>3>4>1	2A>1B~1A>7>2C	A2	+	=	[2,81-83]
Olanzapine	Zyprexa	2>4>1	2A>2C>6>1F~7>1B>1 D>1e>1A	H1,M1,A1	++++	$\uparrow$	[2,52,81-83]
Paliperidone	Invega	3>2>1>4	2A~7>2C>2B>1B	H1,A1,A2		$\uparrow$	[83]
Quetiapine	Seroquel	3>2>1	7>1A>2A>1B	H1,A1,A2	+++	=	[2,52,81-83]
Risperidone	Risperdal	2>4~5>3>1	2A>7>1D>1B~2B~2C >1B>1A~5A	H1,A1,A2	++	$\uparrow$	[2,52,81-83]
Sertindole	Serdolect	2~3>4	2A>2C>6>7>1B>1D> 1A>1F>1e	A1	+++	nr	[2,81,82]
Ziprasidone	Geodon	2>3>1~4>5	2A>1B~1D~7>2C>6> 1A	H1,M1,A1	=/+	nr	[2,81,82]
<b>3<sup>rd</sup> generation</b> Aripiprazole	Abilify	2>3>1	2B>1A>7>2A~2C>1D	H1,A1	=/+	=	[81,83]

**Table 1.** Antipsychotic medications: Receptor binding affinities and metabolic activities.

<sup>a</sup> Abbreviations: IR-insulin resistance; = no significant change; + relative increase from slight (+) to major (++++); increased insulin resistance; H1 - H<sub>1</sub> histamine receptor, A1 -  $\alpha_1$ -adrenergic receptor, A2 -  $\alpha_2$ -adrenergic receptor, M1 - muscarinic acetylcholine receptor M<sub>1</sub>.

<sup>b</sup> Ligand type: agonist - black; reverse agonist/antagonist - red; allosteric effect - blue.

<sup>c</sup> Additional data from pharmaceutical manufacturers.

<sup>d</sup> Not reported.

# References

- 1. American Diabetes Association (2004) Consensus development conference on antipsychotic drugs and obesity and diabetes. *J.Clin.Psychiatry*. 65, 267-272
- 2. Richtand, N.M. *et al.* (2007) Dopamine and serotonin receptor binding and antipsychotic efficacy. *Neuropsychopharmacology* 32, 1715-1726
- 3. Nasrallah, H.A. (2008) Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. *Mol.Psychiatry* 13, 27-35
- 4. Werkman, T.R. *et al.* (2006) Dopamine receptor pharmacology: interactions with serotonin receptors and significance for the aetiology and treatment of schizophrenia. *CNS.Neurol. Disord.Drug Targets.* 5, 3-23
- 5. Carlsson, A. (1988) The current status of the dopamine hypothesis of schizophrenia. *Neuropsychopharmacology* 1, 179-186
- 6. Missale, C. *et al.* (1998) Dopamine receptors: from structure to function. *Physiol.Rev.* 78, 189-225
- 7. Beaulieu, J.M. and Gainetdinov, R.R. (2011) The physiology, signaling, and pharmacology of dopamine receptors. *Pharmacol.Rev.* 63, 182-217
- 8. Berger, M. et al. (2009) The expanded biology of serotonin. Annu. Rev. Med. 60, 355-366
- 9. Jeste, D.V. *et al.* (1998) Adverse neurobiological effects of long-term use of neuroleptics: human and animal studies. *J.Psychiatr.Res.* 32, 201-214
- 10. Meltzer,H.Y. (1999) The role of serotonin in antipsychotic drug action. *Neuropsychopharmacology* 21, 106S-115S
- 11. Panagiotopoulos, C. *et al.* (2010) First do no harm: promoting an evidence-based approach to atypical antipsychotic use in children and adolescents. *J.Can.Acad.Child Adolesc.Psychiatry* 19, 124-137
- 12. Gray, J.A. and Roth, B.L. (2007) Molecular targets for treating cognitive dysfunction in schizophrenia. *Schizophr.Bull.* 33, 1100-1119
- 13. Parsons, B. *et al.* (2009) Weight effects associated with antipsychotics: a comprehensive database analysis. *Schizophr.Res.* 110, 103-110
- 14. Pramyothin, P. and Khaodhiar, L. (2010) Metabolic syndrome with the atypical antipsychotics. *Curr.Opin.Endocrinol.Diabetes Obes.* 17, 460-466
- 15. Sikich,L. *et al.* (2008) Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study. *Am.J.Psychiatry* 165, 1420-1431
- 16. Correll,C.U. *et al.* (2009) Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. *JAMA* 302, 1765-1773

- 17. Cali,A.M. and Caprio,S. (2008) Obesity in children and adolescents. *J.Clin.Endocrinol.Metab* 93, S31-S36
- 18. American Psychiatric Association (1997) Practice guide for the treatment of patients with schizophrenia. *American Psychiatric Association* 1, 1-20
- 19. Nedungadi, T.P. and Clegg, D.J. (2009) Sexual dimorphism in body fat distribution and risk for cardiovascular diseases. *J.Cardiovasc.Transl.Res.* 2, 321-327
- 20. Santosa, S. and Jensen, M.D. (2008) Why are we shaped differently, and why does it matter? *Am.J.Physiol Endocrinol.Metab* 295, E531-E535
- 21. Arner, P. (2001) Regional differences in protein production by human adipose tissue. *Biochem. Soc.Trans.* 29, 72-75
- 22. Gregoire, F.M. (2001) Adipocyte differentiation: from fibroblast to endocrine cell. *Exp.Biol. Med.*(*Maywood.*) 226, 997-1002
- 23. Rosen,E.D. and Spiegelman,B.M. (2000) Molecular regulation of adipogenesis. *Annu.Rev.Cell Dev.Biol.* 16, 145-171
- 24. Jocken, J.W. and Blaak, E.E. (2008) Catecholamine-induced lipolysis in adipose tissue and skeletal muscle in obesity. *Physiol Behav.* 94, 219-230
- 25. Tavernier, G. *et al.* (2005) Norepinephrine induces lipolysis in beta1/beta2/beta3-adrenoceptor knockout mice. *Mol.Pharmacol.* 68, 793-799
- 26. Dardeno, T.A. et al. (2010) Leptin in human physiology and therapeutics. Front Neuroendocrinol. 31, 377-393
- 27. Hukshorn, C.J. and Saris, W.H. (2004) Leptin and energy expenditure. *Curr.Opin.Clin. Nutr.Metab Care* 7, 629-633
- 28. Shetty, S. *et al.* (2009) Adiponectin in health and disease: evaluation of adiponectin-targeted drug development strategies. *Trends Pharmacol.Sci.* 30, 234-239
- 29. Lara-Castro, C. *et al.* (2007) Adiponectin and the metabolic syndrome: mechanisms mediating risk for metabolic and cardiovascular disease. *Curr.Opin.Lipidol.* 18, 263-270
- 30. Kim, J.H. et al. (2009) Interleukin-6 and insulin resistance. Vitam. Horm. 80, 613-633
- 31. Fain, J.N. (2010) Release of inflammatory mediators by human adipose tissue is enhanced in obesity and primarily by the nonfat cells: a review. *Mediators.Inflamm.* 2010, 513948
- 32. Goldstein, D.S. *et al.* (1999) Sources and physiological significance of plasma dopamine sulfate. *J.Clin.Endocrinol.Metab.* 84, 2523-2531
- 33. Eisenhofer, G. *et al.* (1997) Substantial production of dopamine in the human gastrointestinal tract. *J.Clin.Endocrinol.Metab.* 82, 3864-3871
- 34. Brown, S. et al. (2003) Catecholamines in a macrophage cell line. J.Neuroimmunol. 135, 47-55

- 35. Musso,N.R. *et al.* (1996) Catecholamine content and in vitro catecholamine synthesis in peripheral human lymphocytes. *J.Clin.Endocrinol.Metab* 81, 3553-3557
- 36. Eisenhofer, G. et al. (1999) Dopamine sulphate: an enigma resolved. Clin.Exp.Pharmacol. Physiol.Suppl. 26, S41-S53
- 37. Ghosh, D. (2005) Three-dimensional structures of sulfatases. Methods Enzymol. 400, 273-293
- 38. Matzner, U. *et al.* (2009) Saposin B-dependent reconstitution of arylsulfatase A activity in vitro and in cell culture models of metachromatic leukodystrophy. *J.Biol.Chem.* 284, 9372-9381
- 39. Borcherding, D.C. *et al.* (2011) Dopamine receptors in human adipocytes: Regulation and functions. *PLoS.One.* 6, e25537
- 40. Onasch, A. *et al.* (2000) Effect of intravenous dopamine infusion on plasma concentrations of dopamine and dopamine sulfate in men, during and up to 18 h after infusion. *Eur.J.Clin.Pharmacol.* 55, 755-759
- 41. Pivonello, R. *et al.* (2007) Novel insights in dopamine receptor physiology. *Eur.J.Endocrinol.* 156 Suppl 1, S13-S21
- 42. Neve,K.A. et al. (2004) Dopamine receptor signaling. J.Recept.Signal.Transduct.Res. 24, 165-205
- 43. Nisoli, E. *et al.* (1992) Biochemical and functional identification of a novel dopamine receptor subtype in rat brown adipose tissue. Its role in modulating sympathetic stimulation-induced thermogenesis. *J.Pharmacol.Exp.Ther.* 263, 823-829
- 44. Brandebourg, T.D. *et al.* (2007) Adipocyte prolactin: regulation of release and putative functions. *Diabetes, Obesity and Metabolism* 9, 364-377
- 45. Kok, P. *et al.* (2006) Activation of dopamine D2 receptors simultaneously ameliorates various metabolic features of obese women. *Am.J.Physiol Endocrinol Metab* 291, E1038-E1043
- 46. Sakowski, S.A. *et al.* (2006) Differential tissue distribution of tryptophan hydroxylase isoforms 1 and 2 as revealed with monospecific antibodies. *Brain Res.* 1085, 11-18
- 47. Geeraerts, B. et al. (2011) Influence of acute tryptophan depletion on gastric sensorimotor function in humans. Am.J.Physiol Gastrointest.Liver Physiol 300, G228-G235
- 48. Ni,W. and Watts,S.W. (2006) 5-hydroxytryptamine in the cardiovascular system: focus on the serotonin transporter (SERT). *Clin.Exp.Pharmacol.Physiol* 33, 575-583
- Kinoshita, M. *et al.* (2010) Regulation of adipocyte differentiation by activation of serotonin (5-HT) receptors 5-HT2AR and 5-HT2CR and involvement of microRNA-448-mediated repression of KLF5. *Mol.Endocrinol.* 24, 1978-1987
- 50. Stunes, A.K. *et al.* (2011) Adipocytes express a functional system for serotonin synthesis, reuptake and receptor activation. *Diabetes Obes.Metab* 13, 551-558
- 51. Millan, M.J. et al. (2008) Signaling at G-protein-coupled serotonin receptors: recent advances

and future research directions. Trends Pharmacol.Sci. 29, 454-464

- 52. Meltzer,H.Y. and Massey,B.W. (2011) The role of serotonin receptors in the action of atypical antipsychotic drugs. *Curr.Opin.Pharmacol.* 11, 59-67
- 53. Millan, M.J. (2011) MicroRNA in the regulation and expression of serotonergic transmission in the brain and other tissues. *Curr.Opin.Pharmacol.* 11, 11-22
- 54. Watanabe, H. et al. (2011) Role of peripheral serotonin in glucose and lipid metabolism. *Curr.Opin.Lipidol.* 22, 186-191
- 55. Li,Q. *et al.* (2012) Heparin-binding EGF-like growth factor (HB-EGF) mediates 5-HT-induced insulin resistance through activation of EGF receptor-ERK1/2-mTOR pathway. *Endocrinology* 153, 56-68
- 56. Case, M. *et al.* (2010) The potential role of appetite in predicting weight changes during treatment with olanzapine. *BMC*.*Psychiatry* 10, 72
- 57. Fountaine, R.J. *et al.* (2010) Increased food intake and energy expenditure following administration of olanzapine to healthy men. *Obesity.(Silver.Spring)* 18, 1646-1651
- 58. Kluge, M. *et al.* (2007) Clozapine and olanzapine are associated with food craving and binge eating: results from a randomized double-blind study. *J. Clin. Psychopharmacol.* 27, 662-666
- 59. Warren, M.P. (2011) Endocrine manifestations of eating disorders. *J.Clin.Endocrinol.Metab* 96, 333-343
- 60. Jin,H. *et al.* (2008) Impact of atypical antipsychotic therapy on leptin, ghrelin, and adiponectin. *Schizophr.Res.* 100, 70-85
- 61. Wang,H.C. et al. (2006) Rapid leptin elevation after initiation of olanzapine? Neuropsychobiology 54, 182-185
- 62. Wang, C.J. *et al.* (2006) Serum free Fatty acids and glucose metabolism, insulin resistance in schizophrenia with chronic antipsychotics. *Biol.Psychiatry* 60, 1309-1313
- 63. Kaddurah-Daouk, R. *et al.* (2007) Metabolomic mapping of atypical antipsychotic effects in schizophrenia. *Mol.Psychiatry* 12, 934-945
- 64. Albaugh, V.L. *et al.* (2011) A double blind, placebo-controlled, randomized crossover study of the acute metabolic effects of olanzapine in healthy volunteers. *PLoS.One.* 6, e22662
- 65. Bai, Y.M. *et al.* (2009) Association of adiponectin and metabolic syndrome among patients taking atypical antipsychotics for schizophrenia: a cohort study. *Schizophr.Res.* 111, 1-8
- 66. Kluge, M. *et al.* (2009) Effects of clozapine and olanzapine on cytokine systems are closely linked to weight gain and drug-induced fever. *Psychoneuroendocrinology* 34, 118-128
- 67. Zhang,X.Y. *et al.* (2004) Changes in serum interleukin-2, -6, and -8 levels before and during treatment with risperidone and haloperidol: relationship to outcome in schizophrenia. *J.Clin. Psychiatry* 65, 940-947

- 68. Cope, M.B. *et al.* (2005) Antipsychotic drug-induced weight gain: development of an animal model. *Int.J.Obes.* (*Lond*) 29, 607-614
- 69. Weston-Green, K. *et al.* (2011) Olanzapine treatment and metabolic dysfunction: a dose response study in female Sprague Dawley rats. *Behav.Brain Res.* 217, 337-346
- 70. Albaugh, V.L. *et al.* (2006) Hormonal and metabolic effects of olanzapine and clozapine related to body weight in rodents. *Obesity*.(*Silver*.Spring) 14, 36-51
- 71. Albaugh, V.L. *et al.* (2012) Atypical antipsychotics rapidly and inappropriately switch peripheral fuel utilization to lipids, impairing metabolic flexibility in rodents. *Schizophr.Bull.* 38, 153-166
- 72. Minet-Ringuet, J. et al. (2007) Alterations of lipid metabolism and gene expression in rat adipocytes during chronic olanzapine treatment. *Mol.Psychiatry* 12, 562-571
- 73. Albaugh, V.L. *et al.* (2010) Olanzapine promotes fat accumulation in male rats by decreasing physical activity, repartitioning energy and increasing adipose tissue lipogenesis while impairing lipolysis. *Mol.Psychiatry*
- 74. Vestri,H.S. *et al.* (2007) Atypical antipsychotic drugs directly impair insulin action in adipocytes: effects on glucose transport, lipogenesis, and antilipolysis. *Neuropsycho-pharmacology.* 32, 765-772
- 75. Yang,L.H. et al. (2007) Olanzapine induces SREBP-1-related adipogenesis in 3T3-L1 cells. *Pharmacol.Res.* 56, 202-208
- 76. Cornier, M.A. (2011) Is your brain to blame for weight regain? *Physiol Behav.* 104, 608-612
- 77. Alexander,G.C. *et al.* (2011) Increasing off-label use of antipsychotic medications in the United States, 1995-2008. *Pharmacoepidemiol.Drug Saf* 20, 177-184
- 78. Shen, W.W. (1999) A history of antipsychotic drug development. Compr. Psychiatry 40, 407-414
- 79. Hippius, H. (1999) A historical perspective of clozapine. J. Clin. Psychiatry 60 Suppl 12, 22-23
- 80. Zuvekas, S.H. (2005) Prescription drugs and the changing patterns of treatment for mental disorders, 1996-2001. *Health Aff.(Millwood.)* 24, 195-205
- 81. Roth,B.L. *et al.* (2003) Atypical antipsychotic drug actions: unitary or multiple mechanisms for ΓÇÿatypicalityΓÇÖ? *Clinical Neuroscience Research* 3, 108-117
- 82. Seeman, P. (2002) Atypical antipsychotics: mechanism of action. Can.J.Psychiatry 47, 27-38
- 83. Harmar, A.J. *et al.* (2009) IUPHAR-DB: the IUPHAR database of G protein-coupled receptors and ion channels. *Nucleic Acids Res.* 37, D680-D685
- 84. Potkin, S.G. *et al.* (2007) Efficacy and tolerability of asenapine in acute schizophrenia: a placeboand risperidone-controlled trial. *J.Clin.Psychiatry* 68, 1492-1500